The thing with the HRIA was that as a condition of receiving funding, all the work, including work in progress, had to be submitted to a searchable database so that everyone else receiving funding could see the work and use it to advance their own work—because above anything else, we had a mandate to get advances and therapies to the patients as quickly as possible. The HRIA still allowed for patent filings, but everything, everything, was cross-licensed for the length of the patent, for a statutory fee that went into effect only after a product went to market.

T h e o r i g i n a l i t y r e q u i r e m e n t a r t i c u l a t e d i n T h e T r a d e - M a r k C a s e s a n d B u r r o w - G i l e s r e m a i n s t h e t o u c h s t o n e o f c o p y r i g h t p r o t e c t i o n t o d a y . S e e G o l d s t e i n v . C a l i f o r n i a , 4 1 2 U . S . 5 4 6 , 5 6 1 - 5 6 2 ( 1 9 7 3 ) . I t i s t h e v e r y " p r e m i s e o f c o p y r i g h t l a w . " M i l l e r v . U n i v e r s a l C i t y S t u d i o s , I n c . , 6 5 0 F . 2 d 1 3 6 5 , 1 3 6 8 ( C A 5 1 9 8 1 ) . L e a d i n g s c h o l a r s a g r e e o n t h i s p o i n t . A s o n e p a i r o f c o m m e n t a t o r s s u c c i n c t l y p u t s i t : " T h e o r i g i n a l i t y r e q u i r e m e n t i s c o n s t i t u t i o n a l l y m a n d a t e d f o r a l l w o r k s . "